New hope for lung cancer patients: drug cocktail targets relapsed stage III disease

NCT ID NCT05568212

Recruiting now Disease control Sponsor: Fondazione Ricerca Traslazionale Source: ClinicalTrials.gov ↗

First seen Dec 11, 2025 · Last updated May 20, 2026 · Updated 21 times

Summary

This study is for people with stage III non-small-cell lung cancer whose cancer has returned after standard chemoradiation and the drug durvalumab. It tests whether adding extra immune therapy or a targeted pill (olaparib) to standard chemotherapy can help them live longer. About 176 adults will be randomly assigned to different treatment combinations to see which works best.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER PATIENTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
RECRUITING

Roma, RM, 00144, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-SMALL-CELL LUNG CANCER PATIENTS NON-SMALL-CELL LUNG CANCER PATIENTS